Table 1 Immune checkpoint inhibitors and their US FDA/EMA/China NMPA approved indications
From: Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
Immune checkpoint inhibitor | Targets | US FDA/EMA approved indications | China NMPA approved indications |
|---|---|---|---|
Pembrolizumab | PD-1 | Melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin’s lymphoma, urothelial carcinoma, MSI-H/dMMR* colorectal cancer, MSI-H/dMMR cancers, gastric cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, small cell lung cancer, esophageal carcinoma, endometrial cancer | Melanoma, non-small cell lung cancer |
Nivolumab | PD-1 | Melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin’s lymphoma, head and neck cancer, urothelial carcinoma, MSI-H/dMMR colorectal cancer, hepatocellular carcinoma, small cell lung cancer | Non-small cell lung cancer |
Atezolizumab | PD-L1 | Urothelial cancer, non-small cell lung cancer, breast cancer, small cell lung cancer | Non-small cell lung cancer |
Durvalumab | PD-L1 | Urothelial carcinoma, non-small cell lung cancer | Â |
Avelumab | PD-L1 | Merkel cell carcinoma, urothelial carcinoma, renal cell carcinoma | Â |
Cemiplimab | PD-1 | Cutaneous squamous cell carcinoma | Â |
Ipilimumab | CTLA4 | Melanoma, metastatic, renal cell carcinoma, MSI-H/dMMR colorectal cancer | Â |
Toripalimab | PD-1 | Â | Melanoma |
Sintilimab | PD-1 |  | Hodgkin’s lymphoma |
Camrelizumab | PD-1 |  | Hodgkin’s lymphoma |
Tislelizumab | PD-1 |  | Hodgkin’s lymphoma |